307750 — Kukjeon Pharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00
- KR₩287bn
- KR₩302bn
- KR₩122bn
- 40
- 13
- 26
- 11
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 80,623 | 85,354 | 103,711 | 121,998 |
Cost of Revenue | |||||
Gross Profit | — | 14,518 | 17,946 | 19,515 | 25,277 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 38.2 | 74,830 | 79,219 | 100,201 | 115,497 |
Operating Profit | -38.2 | 5,793 | 6,135 | 3,510 | 6,501 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -35.4 | -2,315 | 5,084 | 11,088 | 1,738 |
Provision for Income Taxes | |||||
Net Income After Taxes | -33.9 | -3,317 | 4,038 | 8,877 | 4,692 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -33.9 | -3,317 | 4,038 | 8,948 | 4,824 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -33.9 | -3,317 | 4,038 | 8,948 | 4,824 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -6.28 | -92.6 | 91.5 | 183 | 98.3 |
Dividends per Share |